Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medicines For Europe Urges Intervention In Inflation Crisis

Industry Conditions Have Exacerbated Impact Of Ukraine War And COVID-19

Executive Summary

Medicines for Europe has called for alterations to regulations concerning the off-patent drug sector, which it says will allow the industry to respond more effectively to the region’s dramatic rise in inflation.

You may also be interested in...

Ukraine War Puts The Pharmaceutical Industry To The Test

Pharmaceutical leaders are responding to the many and varied challenges arising from the war in Ukraine.

Medicines For Europe Recommends Changes To EU Pharmaceutical Legislation

Medicines for Europe has offered several suggestions to re-evaluate the EU’s pharmaceutical legislation, including moves to allow off-patent competition from day one of exclusivity expiry as well as to ensure a competitive and balanced single market for multi-source medicines. The European off-patent industry body also discussed access issues, unmet medical needs and incentives in its feedback.

Medicines For Europe Calls For Security Of Supply Legislation

Medicines for Europe has urged the European Commission to enshrine security of supply considerations for essential medicines into legislature. Without these, additional cost containment measures for off-patent medicines under consideration by member states may ultimately threaten access by making production unsustainable for manufacturers.


Latest News



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts